A Validation Study of the NightOwl PAT-based Home Sleep Apnea Test
Launched by ECTOSENSE NV · Dec 9, 2019
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
The objective of this study is to evaluate the performance of a miniaturized sleep apnea test, called NightOwl. The system consists of a sensor placed on the fingertip and a cloud-based analytics software. The sensor acquires accelerometer and photoplethysmographic data. The software derives actigraphy from the former, and blood oxygen saturation and peripheral arterial tone (PAT), among other features, from the latter. In order to assess NightOwl's performance, The investigators will compare the respiratory event index (REI), defined as the number of respiratory events per hour of sleep, d...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with an indication for an in-lab polysomnography
- Exclusion Criteria:
- • Intellectually disabled people
- • People younger than 13 years of age.
About Ectosense Nv
Ectosense NV is a pioneering medical technology company dedicated to advancing sleep health through innovative diagnostic solutions. With a focus on developing non-invasive monitoring devices, Ectosense aims to empower patients and healthcare providers with accurate and actionable insights into sleep disorders, particularly obstructive sleep apnea. By leveraging cutting-edge technology and clinical research, the company strives to enhance patient outcomes and improve the overall management of sleep-related conditions, positioning itself as a leader in the field of sleep medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami Lakes, Florida, United States
Plantation, Florida, United States
Plantation, Florida, United States
Patients applied
Trial Officials
Frederik Massie, MSc
Study Director
Ectosense NV
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials